- Home
- ENTO vs CAPS Comparison
ENTO vs CAPS Comparison
Compare ENTO & CAPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTO
- CAPS
- Stock Information
- Founded
- ENTO 2014
- CAPS 1987
- Country
- ENTO United States
- CAPS United States
- Employees
- ENTO N/A
- CAPS N/A
- Industry
- ENTO Biotechnology: Pharmaceutical Preparations
- CAPS
- Sector
- ENTO Health Care
- CAPS
- Exchange
- ENTO Nasdaq
- CAPS NYSE
- Market Cap
- ENTO 2.5M
- CAPS 3.0M
- IPO Year
- ENTO 2016
- CAPS N/A
- Fundamental
- Price
- ENTO $0.41
- CAPS $2.36
- Analyst Decision
- ENTO
- CAPS
- Analyst Count
- ENTO 0
- CAPS 0
- Target Price
- ENTO N/A
- CAPS N/A
- AVG Volume (30 Days)
- ENTO 98.4K
- CAPS 1.0M
- Earning Date
- ENTO 05-20-2025
- CAPS 04-02-2025
- Dividend Yield
- ENTO N/A
- CAPS N/A
- EPS Growth
- ENTO N/A
- CAPS N/A
- EPS
- ENTO N/A
- CAPS N/A
- Revenue
- ENTO N/A
- CAPS $44,876,000.00
- Revenue This Year
- ENTO N/A
- CAPS N/A
- Revenue Next Year
- ENTO N/A
- CAPS N/A
- P/E Ratio
- ENTO N/A
- CAPS N/A
- Revenue Growth
- ENTO N/A
- CAPS N/A
- 52 Week Low
- ENTO $0.19
- CAPS $1.72
- 52 Week High
- ENTO $4.23
- CAPS $16.18
- Technical
- Relative Strength Index (RSI)
- ENTO 37.79
- CAPS N/A
- Support Level
- ENTO $0.39
- CAPS N/A
- Resistance Level
- ENTO $0.61
- CAPS N/A
- Average True Range (ATR)
- ENTO 0.07
- CAPS 0.00
- MACD
- ENTO -0.01
- CAPS 0.00
- Stochastic Oscillator
- ENTO 8.93
- CAPS 0.00
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
About CAPS CAPSTONE HOLDING CORP
Capstone Holding Corp operates through its wholly-owned subsidiary as a construction materials company, which distributes manufactured and natural stone cladding products, natural stone landscape products, and related goods for residential and commercial construction.